Bibliografia
 
  1. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int. 2012 Oct;32(9):1333-41.
  2. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr;37(4):748-55.
  3. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther. 2004 Apr;9(2):257-62.
  4. Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355-62.
  5. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008 Sep;48(3):750-8.
  6. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008 May;48(5):747-55.
  7. Gallego A, Sheldon J, García-Samaniego J, et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat. 2008.
  8. Karatayli E, Karayalçin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761-8.
  9. Salpini R, Alteri C, Cento V, et al. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Accepted on J Med Virol.
  10. Marcellin P, et al. EASL 2012. Poster 530
  11. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012 Jun;19(6):377-86.
  12. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010 Jan;51(1):73-80.
  13. Corrigendum to: ‘‘EASL clinical practice guidelines: Management of chronic hepatitis B virus infection’’ [J Hepatol 2012;57:167–185].
  14. van Bömmel F, Trojan J, Deterding K, et al. Evolution of adefovirresistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. Antivir Ther. 2012;17(6):1049-58.
  15. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011 Feb;60(2):247-54.
  16. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012 Mar;56(3):520-6.
  17. Salpini R, Svicher V, Cento V, et al. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. Antiviral Res. 2011 Nov;92(2):382-5.
  18. Mirandola S, Campagnolo D, Bortoletto G, et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011 Jul;18(7):e212-6.
  19. Tuma P, Pineda JA, Labarga P, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther. 2011;16(4):585-9.
  20. Billioud G, Pichoud C, Parent R, Zoulim F. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants. J Hepatol. 2012 Jun;56(6):1269-75.
  21. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008 Jul;48(1):88-98.
© Effetti srl